期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

p57^(kip2)和cyclin D1在人脑胶质瘤中的表达和临床意义 被引量：1

Expression of p57^(kip2) and cyclin D1 in human glioma and its clinical significance
下载PDF
导出
摘要 目的探讨p57kip2蛋白、cyclin D1蛋白在人脑胶质瘤中的表达情况及其临床意义。方法采用免疫组织化学SP法检测p57kip2、cyclin D1在55例人脑胶质瘤和10例正常脑组织中的表达。结果在55例胶质瘤中,p57kip2蛋白阳性率为38.2%(21/55),显著低于正常脑组织(80%,P<0.05)。p57kip2蛋白表达在低度恶性(Ⅰ-Ⅱ级)组显著高于高度恶性(Ⅲ-Ⅳ级)组(P<0.05),生存时间≥2年组显著高于<2年组(P<0.05)。脑胶质瘤中Cyclin D1蛋白阳性率为54.5%(30/55),显著高于正常脑组织(10%,P<0.05)。cyclin D1蛋白表达在高度恶性(Ⅲ-Ⅳ级)组显著高于低度恶性(Ⅰ-Ⅱ级)组(P<0.05),生存时间<2年组显著高于≥2年组(P<0.05)。p57kip2蛋白的表达与cyclinD1蛋白的表达存在负相关(rs=-0.277,P<0.05)。结论p57kip2蛋白和cyclin D1蛋白在脑胶质瘤中存在异常表达,p57kip2蛋白和cyclin D1蛋白的表达程度与脑胶质瘤的分化程度、预后相关。 Objective To investigate the expression of p57^kip2 and cyclin D1 in human brain glioma and its clinical significance. Methods The expression of p57^kip2 and cyclin D1 was detected by SP immunohistochemical technique in brain glioma （n=55） and normal brain tissues （n = 10）. Results Positive rate of p57^kip2 protein in the 55 cases of brain glioma was 38.2% （21/55）, significantly lower than that in normal brain tissues （80%, P〈0.05）. p57^kip2 positivity in low malignancy group （ Ⅰ-Ⅱ grade） was significantly higher than that in high malignancy group （ Ⅲ- Ⅳ grade） （P〈0.05） ; in survival time ≥2 years group, it was significantly higher than that in 〈2 years group （P〈0.05）. Positive rate of cyclin D1 protein in brain glioma was 54.5 % （30/55）, significently higher than that in normal brain tissues （10%, P〈0. 05）. Cyclin D1 expression in high malignancy group （Ⅲ- Ⅳ grade） was significantly higher than that in low malignancy group （ Ⅰ- Ⅱ grade） （P〈0.01）; in survival time 〈2 years group it was significantly higher than that in ≥2 years group （P〈0.05）. There was a negative correlation between the expression of p57^kip2 and cyclin D1 （rs=-0. 277, P〈0.05）. Conclusion The expression of p57^kip2 protein and cyclin D1 protein is abnormal in glioma, and the expression extent is correlated with tumor differentiation and prognosis.
作者 屈建强 杨涛 周乐 张熙
机构地区 西安交通大学医学院第二附属医院神经外科 安康市中心医院神经外科
出处 《西安交通大学学报（医学版）》 CAS CSCD 北大核心 2007年第6期662-664,共3页 Journal of Xi’an Jiaotong University（Medical Sciences）
基金 陕西省科技计划基金资助项目[No.2006K09-G2(12)]
关键词 P57^KIP2蛋白 CYCLIN D1蛋白 脑胶质瘤 免疫组织化学 p57^kip2 protein cyclin D1 protein glioma immunohistochemistry
分类号 R739.41 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Sherr CJ. Cancer cell cycles [J]. Science, 1996, 274(5293): 1672-1677.
  • 2Ito Y, Yoshida H, Nakano K, et al. Expression of p57/ Kip2 protein in normal and neoplastic thyroid tissues [J]. Int J Mol Med, 2002, 9(4):373-376.
  • 3Ito Y, Takeda T, Sasaki Y, et al. Expression of p57/ Kip2 protein in extrahepatic bile duct arcinoma and intrahepatic cholangiocellular carcinoma [J]. Liver, 2002, 22(2) :145-149.
  • 4Lee MH, Reynisdottir I, Massague J. Cloning of p57^kip2 , a cyclin-dependent kinase inhibitor with unique domain instructure and tissued distribution[J]. Genes Dev, 1995, 9(6):639-649.
  • 5Lai S, Goepfert H, Gillenwater AM, et al. Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57kip2 gene in head and neck squamous cell carcinoma [J]. Clin Cancer Res, 2000, 6(8):3172-3176.
  • 6Matsuoka S, Edwards MS, Bai C, et al. p57kip2, a structurally distinct member of the p21cipl Cdk inhibitor family, is a candicate tumor suppressor gene [J]. Genes Dev, 1995, 9(6):650- 662.
  • 7Nakai S, Masaki T, Shiratori Y, et al. Expression of p57 (kip2) in hepatocellular carcinoma: relationship between tumor differentiation and patient surrival [J]. Int J Oncol, 2002, 20 (4) :769-775.
  • 8Nakamura M, Konishi N, Hiasa Y, et al. Frequent alterations of cell-cycle regulators in astrocytic tumors as detected by molecular genetic and immunohistochemical analyses[J]. Brain Tumor Pathol, 1998, 15(2) :83-88.
  • 9Park SH, Suh YL. Expression of cyclin A and topoisomerase Ⅱ alpha of oligodendrogliomas is correlated with turnout grade, MIB-1 labelling index and survival [J]. Histopathol, 2003, 42 (4) :395-402.
  • 10周正平,王进京,郑洪,苏俊,肖庆邦.乳腺浸润性导管癌中cyclinD_1、p57^(KIP2)的表达及意义[J].肿瘤防治研究,2005,32(8):476-478. 被引量：6

二级参考文献8

  • 1Charles J , Sherr, The Pezcoller Lecture : Cancer Cell Cycles Revisited[J ]. Cancer Research, 2000,60 : 3689-3695.
  • 2Fattaneh A, Tavassoli , Peter Devilee. WHO classification of tumours. Pathology & genetics, tumours of the breast and female genital organs[M]. Lyon: IARC Press, 2003. 10-19.
  • 3Toru Motokura, Theodora Bloom, Hyung Goo Kim, et al. A novel cyclin encoded by a bcll-linked candidate oncogene[J].Nature, 1991,350:512-515.
  • 4Robert L,Sutherland,Elizabeth A, et al. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models[J]. Breast Cancer Res, 2002,4 ( 1 ) : 14-17.
  • 5Shuhei M, Michael C, Edwards,et al. p57KIP2,a structurally distinct member of the p21^CIP1 Cdk inhibitor family,is a candidate tumor suppressor gene[J]. Genes Dev, 1995,9 : 650-662.
  • 6Pumin Zhang, Nanette J, Liegeois, et al. Altered cell differentiation and proliferation in mice lacking p57^KIP2 indicates a role in Beckwith-Wiedemenn syndrome[J]. Nature, 1997,387(6629):151-158.
  • 7Tarlochan Nijjar, Don Wigington, James C, et al. p57^KIP2 Expression and Loss of heterozygosity during Immortal Conversion of Cultured Human Mammary Epithelial Cells[J]. Cancer Research, 1999,59( ) : 5112-5118.
  • 8Mong-Hong Lee, Inga Reynisdottir,Joan Massague. Cloning of p57^KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution[J]. Genes & Development,1995,9(6) :639-649.

共引文献5

同被引文献10

  • 1Sherr CJ. Cancer cell cycles [J]. Science, 1996, 274(5293): 1672-1677.
  • 2Ito Y, Yoshida H, Nakano K, et al. Expression of p57/ Kip2 protein in normal and neoplastic thyroid tissues [J]. Int J Mol Med, 2002, 9(4):373-376.
  • 3Ito Y, Takeda T, Sasaki Y, et al. Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma [J]. Liver, 2002, 22(2):145-149.
  • 4Lee MH, Reynisdottir I, Massague J. Cloning of p57^kip2 , a cyclin-dependent kinase inhibitor with unique domain instructure and tissued distribution [J]. Genes Dev, 1995, 9(6):639-649.
  • 5Lai S, Goepfert H, Gillenwater AM, et al. Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57kip2 gene in head and neck squamous cell carcinoma [J]. Clin Cancer Res, 2000, 6(8):3172-3176.
  • 6Nakai S, Masaki T, Shiratori Y, et al. Expression of p57(kip2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival[J]. Int J Oncol, 2002, 20(4): 769-775.
  • 7Huang ZY, Wu Y, Hedrick N, et al. T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21 (CIP1/ WAF 1) expression [JJ. Mol Cell Biol, 2003, 23(2):566-578.
  • 8Weng MS, Ho YS, Lin JK. Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21Waf1/Cip1 expression: involvement of p38 mitogen-activated protein kinase [J]. Biochem Pharmacol, 2005, 69(12) :1815-1827.
  • 9Mitani Y, Oue N, Hamai Y, et al. Histone H3 acetylation is associated with reduced p21 (WAF1/CIP1) expression by gastric carcinoma [J]. J Pathol, 2005, 205(1):65-73.
  • 10Dosaka-Akita H, Hommura F, Mishina T. A Risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21 [J]. Cancer Res, 2001, 61(6) :2500-2504.

引证文献1

二级引证文献4

西安交通大学学报（医学版）
2007年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部